Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, TRIO Health, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV. Dr. Eron disclosed in previous editions that he had received consulting fees from AbbVie, Avexa, Bristol-Myers Squibb, Chimerix, EMD Serono, Inhibitex, Kainos, Koronis, Myriad, Pfizer, Roche Molecular Systems, Tobira, Tibotec/Janssen, and Virco; had received funds for research support from AbbVie, Bristol-Myers Squibb, Merck, Panacos, TaiMed, and Tobira; had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco; and had served on data and safety monitoring boards for TaiMed and Vertex.
Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support from Atea, Gilead Sciences, Merck, Novartis, and ViiV Healthcare and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Merck, Rigel, and ViiV Healthcare. Dr Kuritzkes has disclosed in previous editions that he has received consulting fees from Bionor, Bristol-Myers Squibb, Celera, Gilead Sciences, GlaxoSmithKline, InnaVirVax, Janssen, Merck, Oncolys, Teva, Tobira, and ViroStatics, and ViiV; funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV; and fees for non-CME/CE services from Merck and ViiV.
Sigal Yawetz, MD, has disclosed that she has received consulting fees from Gilead Sciences.
Judith S. Currier, MD, MSc, has no relevant conflicts of interest to report. Dr. Currier disclosed in previous editions that she had received funds for research support from Merck, Schering-Plough, Theratechnologies, Tibotec, and ViiV; had received consulting fees from GlaxoSmithKline and ViiV; had served on advisory boards for Bristol-Myers Squibb, Gilead Sciences, Merck, Pfizer, and Tibotec; and had served on the data and safety monitoring board for Achillion.
Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Elaine P. Seeskin has no relevant conflicts of interest to report.
Petra Cravens, PhD has no relevant conflicts of interest to report.
Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Edward King, MA, has no relevant conflicts of interest to report.
The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:
Kristine Patterson, MD, disclosed that she had received consulting fees from GlaxoSmithKline, had served on the advisory board for Tibotec/Janssen Therapeutics, and had received funds for research support from Abbott, AbbVie, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, and Tibotec/Janssen Therapeutics at the time she contributed to this module.
Kimberly Y. Smith, MD, MPH, disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.
Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tibotec, and Tobira; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.
Rachael M. Andrie, PhD; Sheralee Connors, MA; Michael A. Craig, MSc; Lindsay Edwards, PhD; Kerry Garza, PhD; Deborah Janssen, MS; Kiran D. Mir-Hudgeons, PhD; Kristen Rosenthal, PhD; and Heather Stieglitz, PhD, had no relevant conflicts of interest to report at the time they contributed to this module.
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.
If you have credit related queries or a complaint, please contact: skelley@clinicaloptions.com.
inPractice Hepatology current certification periodThis program is intended for physicians and other healthcare professionals involved in the medical management of patients with or at risk of viral hepatitis.
Goal:The goal of this activity is to improve learners’ knowledge and competence regarding the clinical management of patients with viral hepatitis.
Learning Objectives:At the conclusion of this activity, participants should be able to:
Commercial Support
This program is supported by educational grants from AbbVie.
This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.
Goal:The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.
Learning Objectives:At the conclusion of this activity, participants should be able to:
This program is supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp. and ViiV Healthcare.
For inPractice Hepatology and HIV
Physician Continuing Medical Education (for Point of Care CME activities)
inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:
After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.